CAR T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia: A Review of the Phase 1 Clinical Trials
Outcomes in adult acute lymphoblastic leukemia (ALL) remain poor, with long-term disease-free survival rates of 30% to 40%.1 Salvage chemotherapy regimens demonstrate limited success in inducing and maintaining a second remission, and consequently overall survival (OS) at 5 years after relapse is as low as 7%.2 Patients who achieve a [ Read More ]